They included standard of care temozolomide, bevacizumab and irinotecan as drugs identified as beneficial in combination with temozolomide in subsets of patients, as well as compounds targeting different pathways identified as crucial in GBM biology, like mTOR inhibitor everolimus and multikinase inhibitor sorafenib. The gene discussed is MTOR; the disease is glioblastoma.